

# Luigi Nocera

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8786661/luigi-nocera-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

365

citations

8

h-index

16

g-index

134

ext. papers

654

ext. citations

3.1

avg, IF

3.67

L-index

#	Paper	IF	Citations
62	Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. <i>European Urology</i> , <b>2017</b> , 72, 632-640	10.2	93
61	Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. <i>European Urology</i> , <b>2020</b> , 77, 576-580	10.2	38
60	Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. <i>European Urology</i> , <b>2018</b> , 73, 452-461	10.2	29
59	Functional outcomes of clinically high-risk prostate cancer patients treated with robot-assisted radical prostatectomy: a multi-institutional analysis. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2017</b> , 20, 395-400	6.2	16
58	Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , <b>2021</b> , 4, 792-801	6.7	12
57	Rate and Extent of Pelvic Lymph Node Dissection in the US Prostate Cancer Patients Treated With Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e451-e467	3.3	11
56	Differences between rural and urban prostate cancer patients. <i>World Journal of Urology</i> , <b>2021</b> , 39, 2507-2514	2.514	8
55	The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients. <i>Prostate</i> , <b>2021</b> , 81, 339-346	4.2	8
54	Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. <i>International Journal of Urology</i> , <b>2021</b> , 28, 862-869	2.3	8
53	The Impact of Race and Age on Distribution of Metastases in Patients with Prostate Cancer. <i>Journal of Urology</i> , <b>2020</b> , 204, 962-968	2.5	7
52	Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	7
51	Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer. <i>Journal of Urology</i> , <b>2021</b> , 206, 69-79	2.5	7
50	Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis. <i>European Urology Supplements</i> , <b>2017</b> , 16, e1862-e1864	0.9	6
49	Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, 60-68.e1	3.3	6
48	External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 253-260	6.2	6
47	Tumor Size Predicts Muscle-invasive and Non-organ-confined Disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	5
46	Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, 117-124	3.3	5

45	Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores. <i>Prostate</i> , <b>2021</b> , 81, 874-881	4.2	5
44	Incidence rates and contemporary trends in primary urethral cancer. <i>Cancer Causes and Control</i> , <b>2021</b> , 32, 627-634	2.8	4
43	The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 785.e11-785.e17	2.8	4
42	Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. <i>World Journal of Urology</i> , <b>2021</b> , 39, 3781-3787	4	4
41	Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> ,	6.2	4
40	Obesity is associated with adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 75.e17-75.e25	2.8	4
39	Predicting the risk of pT3a stage in cT1 clear cell renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , <b>2021</b> , 47, 1187-1190	3.6	4
38	Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	4
37	The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. <i>World Journal of Urology</i> , <b>2021</b> , 1	4	4
36	Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Journal of Urology</i> , <b>2022</b> , 207, 16-24	2.5	4
35	Improving the stratification of intermediate risk prostate cancer. <i>Minerva Urology and Nephrology</i> , <b>2021</b> ,	2.3	3
34	Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages-A SEER-based Study. <i>European Urology Focus</i> , <b>2021</b> , 7, 1332-1338	5.1	3
33	Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study. <i>International Journal of Urology</i> , <b>2021</b> , 28, 834-839	2.3	3
32	Bladder cancer stage and mortality: urban vs. rural residency. <i>Cancer Causes and Control</i> , <b>2021</b> , 32, 139-145	3.5	3
31	Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aN0M0 Renal Cell Carcinoma Patients. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	3
30	Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. <i>Journal of Clinical Pathology</i> , <b>2021</b> ,	3.9	3
29	Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study. <i>International Journal of Urology</i> , <b>2021</b> , 28, 1247-1252	2.3	3
28	Comparison Between Urothelial and Non-Urothelial Urethral Cancer. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 629692	5.3	3

27	Sex-Related Differences Include Stage, Histology, and Survival in Urethral Cancer Patients. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, 135-143	3.3	2
26	The role of nephrectomy in metastatic renal cell carcinoma in the immuno-oncology era. <i>BJU International</i> , <b>2021</b> , 128, 438-439	5.6	2
25	The effect of race on stage at presentation and survival in upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 788.e7-788.e13	2.8	2
24	Improving the Stratification of Patients With Intermediate-risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, e120-e128	3.3	2
23	The effect of primary urological cancers on survival in men with secondary prostate cancer. <i>Prostate</i> , <b>2021</b> , 81, 1149-1158	4.2	2
22	Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. <i>Cancer Causes and Control</i> , <b>2021</b> , 1	2.8	2
21	Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries. <i>Cancer Epidemiology</i> , <b>2021</b> , 74, 101994	2.8	2
20	Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis.. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 104, 102360	14.4	1
19	Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. <i>Prostate</i> , <b>2022</b> , 82, 78-85	4.2	1
18	Efficacy of local treatment in patients with prostate cancer with clinically pelvic lymph node-positive disease at initial diagnosis.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 164-164	2.2	1
17	Higher Cancer Mortality in Rural Upper Urinary Tract Urothelial Carcinoma Patients. <i>Urologia Internationalis</i> , <b>2021</b> , 105, 624-630	1.9	1
16	Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy. <i>International Journal of Clinical Oncology</i> , <b>2021</b> , 26, 1707-1713	4.2	1
15	Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 789.e9-789.e17	2.8	1
14	The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 369.e9-369.e17	2.8	1
13	Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, e255-e263	3.3	1
12	Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 74.e1-74.e7	2.8	1
11	A Nomogram-Based Model to Predict Respiratory Dysfunction at 6 Months in Non-Critical COVID-19 Survivors.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 781410	4.9	1
10	Response to the letter to the editor: "Don't throw the baby out with the bath water" by Horsley et al.. <i>Prostate</i> , <b>2021</b> ,	4.2	1

9	Robot-assisted Radical Prostatectomy with the Novel Hugo Robotic System: Initial Experience and Optimal Surgical Set-up at a Tertiary Referral Robotic Center.. <i>European Urology</i> , <b>2022</b> ,	10.2	1
8	Sex- and Age-Related Differences in the Distribution of Metastases in Patients With Upper Urinary Tract Urothelial Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 534-540	7.3	0
7	A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer. <i>Cancer Biology and Medicine</i> , <b>2021</b> ,	5.2	0
6	Radical Cystectomy vs. Multimodality Treatment in T2N0M0 Bladder Cancer: A Population-based, Age-matched Analysis. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, e264-e271	3.3	0
5	Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables.. <i>Journal of Racial and Ethnic Health Disparities</i> , <b>2022</b> , 1	3.5	0
4	The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 754996	5.3	
3	Reply by Authors. <i>Journal of Urology</i> , <b>2021</b> , 206, 79	2.5	
2	Re: Hiten D. Patel, Farzana A. Faisal, Bruce J. Trock, et al. Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. <i>Eur Urol</i> 2020;78:360-368. <i>European Urology</i> , <b>2021</b> , 79, e33-e34	10.2	
1	Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , <b>2021</b> , 155, 245-255	7.5	